Connection

ELIZABETH VAUGHAN to Cardiovascular Diseases

This is a "connection" page, showing publications ELIZABETH VAUGHAN has written about Cardiovascular Diseases.
Connection Strength

0.952
  1. Built Environment and Cardiovascular Diseases - Insights from a Global Review. Curr Atheroscler Rep. 2025 Mar 05; 27(1):36.
    View in: PubMed
    Score: 0.095
  2. Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American Heart Association Scientific Sessions. Curr Atheroscler Rep. 2025 Feb 06; 27(1):30.
    View in: PubMed
    Score: 0.094
  3. Highlights of Cardiovascular Disease Prevention Studies?Presented at the 2024 European Society of Cardiology?Congress. Curr Atheroscler Rep. 2024 Dec 02; 27(1):14.
    View in: PubMed
    Score: 0.093
  4. Going from Primary to Primordial Prevention: Is the Juice Worth the Squeeze? Curr Cardiol Rep. 2024 Oct; 26(10):1135-1143.
    View in: PubMed
    Score: 0.091
  5. Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American College of Cardiology Conference. Curr Atheroscler Rep. 2024 Aug; 26(8):367-381.
    View in: PubMed
    Score: 0.090
  6. Global Cardiovascular Research: Gaps and Opportunities. Curr Cardiol Rep. 2023 12; 25(12):1831-1838.
    View in: PubMed
    Score: 0.087
  7. Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 European Society of Cardiology Congress. Curr Atheroscler Rep. 2023 12; 25(12):965-978.
    View in: PubMed
    Score: 0.087
  8. Demographic and Regional Trends of Cardiovascular Diseases and Diabetes Mellitus-Related Mortality in the United States From 1999 to 2019. Am J Med. 2023 07; 136(7):659-668.e7.
    View in: PubMed
    Score: 0.084
  9. A Mistake Not to Be Repeated: What Can We Learn from the Underutilization of Statin Therapy for Efficient Dissemination of Cardioprotective Glucose Lowering Agents? Curr Cardiol Rep. 2022 06; 24(6):689-698.
    View in: PubMed
    Score: 0.077
  10. Correlates of Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes Mellitus (from the Department of Veterans Affairs). Am J Cardiol. 2022 06 01; 172:7-10.
    View in: PubMed
    Score: 0.077
  11. Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans Affairs. Diabetes Care. 2022 02 01; 45(2):372-380.
    View in: PubMed
    Score: 0.077
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.